

Table 2.2. Summary of case–control studies of hepatocellular carcinoma and presence vs absence of hepatitis B surface antigen (HBsAg)

Reference and location	Subjects	Seroprevalence of HBsAg				OR	95% CI	Comments
		Cases		Controls				
		No.	%	No.	%			
Africa								
Bile <i>et al.</i> (1993) Somalia	Men and women	62	41.9	62	11.3	[5.67]	[2.06–16.17]	
Dazza <i>et al.</i> (1993) Mozambique	Men and women	178	66.3	194	13.9	[13.55]	[7.74–23.50]	Adjusted for HCV
Cenac <i>et al.</i> (1995) Niger	Men and women	26	73.1	47	29.8	[6.59]	[2.03–22.28]	
Olubuyide <i>et al.</i> (1997) Ibadan, Nigeria	Men and women	64	59.3	64	50.0	1.46	0.68–18.13	Hospital controls
Kew <i>et al.</i> (1997) South Africa	Men and women	231	53.2	231	8.2	21.8	8.9–53.4	Hospital controls
Omer <i>et al.</i> (2004) Sudan	Men and women	114	43	198	7	9.9	5.2–18.9	Hospital-based cases and community controls
Kirk <i>et al.</i> (2004) The Gambia	Men and women	216	61	408	16	16.7	9.7–28.7	
Americas								
El-Serag <i>et al.</i> (2001) USA	99% Men	823	11	3459	2	9.2	4.5–18.8	Record linkage study in Veterans, HBV status refers to hospital records

Table 2.2. Summary of case-control studies of hepatocellular carcinoma and presence vs absence of hepatitis B surface antigen (HBsAg)

Reference and location	Subjects	Seroprevalence of HBsAg				OR	95% CI	Comments
		Cases		Controls				
		No.	%	No.	%			
Asia								
Yu <i>et al.</i> (1991) Taiwan, China	Men and women	127	86.6	127	16.6	32.7	16.4-65.2	
Fukuda <i>et al.</i> (1993) Japan	Men and women	Male: 287	10.5	287	1.0	8.7	2.5-29.6	OR adjusted for HCV and alcohol Univariate OR in women
		Female: 81	11.1	198	1.5	7.6	2.0-29.4	
Okuno <i>et al.</i> (1994) Guangxi, China	Men and women	186	70.4	48	10.4	20.5	7.7-54.4	Healthy controls
Park <i>et al.</i> (1995) Pusan, Korea	Men and women	540	61.1	808	5.2	37.9	31.4-45.7	Adjusted for age, sex, HCV
Pyong <i>et al.</i> (1994) Osaka, Japan	Korean men and women	90	17	249	3.6	58.2	15.3-221	Adjusted for age, sex, HCV, smoking and alcohol
Tsai <i>et al.</i> (1996) Taiwan, China	Men and women	361	80.3	361	20.7	68.4	20.5-227.8	Health check-up controls
Sun <i>et al.</i> (1996) Taiwan, China	Men and women	58	82.8	225	12.9	27.6	10.7-0.9	Matched (age, sex, residence) analysis and adjusted for anti-HCV
Shin <i>et al.</i> (1996) Pusan, Korea	Men and women	203	65.5	406	3.5	87.4	22.2-344.3	Matched (age and sex) analysis and adjusted for HCV and alcohol

Table 2.2. Summary of case–control studies of hepatocellular carcinoma and presence vs absence of hepatitis B surface antigen (HBsAg)

Reference and location	Subjects	Seroprevalence of HBsAg				OR	95% CI	Comments
		Cases		Controls				
		No.	%	No.	%			
Yu <i>et al.</i> (1997b) Multicentre, China	Men and women	359	66.3	359	23.4	6.4	[4.6–9.1]	
Zhang <i>et al.</i> (1998) Henan, China	Men and women	152	63.2	115	5.2	28.8	11.2–78.8	Hospital controls
Lu <i>et al.</i> (1999) Tzukuan, Taiwan	Men and women	27	40.7	108	25.0	2.1	0.9-5.0	Community controls No case both HCV and HBV negative
Tsai <i>et al.</i> (2001) Taiwan, China	Men and women	263	65	263	22	16.7	9.9-28.1	
Kuang <i>et al.</i> (2005) Thailand	Men and women	34	73.5	68	14.7	16.1	5.9-44.3	
Kumar <i>et al.</i> (2007) India	Men and women	213	61.5	254	3.9	39.0	19.5–77.7	Hospital controls

Table 2.2. Summary of case-control studies of hepatocellular carcinoma and presence vs absence of hepatitis B surface antigen (HBsAg)

Reference and location	Subjects	Seroprevalence of HBsAg				OR	95% CI	Comments
		Cases		Controls				
		No.	%	No.	%			
Europe								
Simonetti <i>et al.</i> (1992) Sicily, Italy	Men and women	1:212 2: 197	15 17	212 197	2 9	8.7 2.0	1.5–50 1.0–4.2	Study 1 included all patients and non-cirrhotic controls; Study 2 included cases with cirrhosis plus cirrhotic controls. All ORs are adjusted for HCV and alcohol
Hadziyannis <i>et al.</i> (1995) Greece	Men and women	65	61.5	130	9.2	18.8	8.2–43.2	Overlap in cases and controls with Kaklamani <i>et al.</i> (1991). Here adjusted for HCV infection
Kaczynski <i>et al.</i> (1996) Sweden	Men and women	73	0	31	0	NR	NR	Past infection more common in cases
Donato <i>et al.</i> (1997) Italy	Men and women	172	23.8	332	5.4	11.4	5.7–22.8	Adjusted for age, sex, residence, HCV status, and heavy alcohol intake
Tagger <i>et al.</i> (1999) Brescia, Italy	Men and women	305	24.4	610	4.1	18.8	10.0–35.2	Hospital controls

Table 2.2. Summary of case–control studies of hepatocellular carcinoma and presence vs absence of hepatitis B surface antigen (HBsAg)

Reference and location	Subjects	Seroprevalence of HBsAg				OR	95% CI	Comments
		Cases		Controls				
		No.	%	No.	%			
Chiesa <i>et al.</i> (2000) Italy	Men and women	With cirrhosis		610		17.6	9.0–34.4	Hospital controls
		142	28					
		Without cirrhosis				20.3	5.7–72.6	
		21	34					
Kuper <i>et al.</i> (2000) Greece	Men and women	333	62.8	632	4.9	48.8	30.5–78.3	Hospital controls – metastatic liver disease and others combined
Gelatti <i>et al.</i> (2005) Italy	Men and women	250	24.0	500	4.4	15.3	8.3–28.1	Hospital controls – adjustment for HCV and coffee consumption
Franceschi <i>et al.</i> (2006a) Italy	Men and women	229	13.9	431	0.9	20.2	6.4–63.6	Hospital controls controlled for HCV, smoking and alcohol